Cell Signaling of Host Defense

国立环境卫生科学研究所呼吸生物学实验室校内研究部宿主防御小组，由Michael B领导。Fessler，MD现在进入了自成立以来在NIEHS的第七年。我们现在已经出版了几份手稿。 自上次年度报告以来的出版物包括： 1)一份鉴定胆固醇转运蛋白ABCG 1在肺中适应性免疫应答中的新作用的报告（德雷珀D等，J Immunology 2012） 2)一份合作出版物报道了肥胖导致小鼠肺中先天免疫应答的异常（Kordonowy等，Am J Respir Cell Mol Biol 2012） 3)一份合作出版物描述了源自CGI-58的信号脂质在炎症和胰岛素作用中的新作用（Lord CC等人，Diabetes 2012）。 4)2篇综述文章描述了胆固醇对肺部炎症和白细胞先天免疫应答的影响（Gowdy K et al，Pulm Pharmacol Ther 2012; Azzam K et al.，Trends Endocrinol Metab 2012）。 5)一位特邀评论员评论了描述胆固醇流出对骨髓干细胞动员的影响的出版物（SurattBT等，细胞干细胞2012） 6)一份报告（出版中）描述了在美国人群中血清变应原特异性免疫球蛋白E（一种特应性的量度）和心肌梗塞之间的新关系（Jaramillo等，过敏临床免疫学杂志2012） 自我们上次报告以来的其他成就包括Fessler博士在俄亥俄州州立大学、约翰霍普金斯大学、密苏里州堪萨斯城大学、东卡罗莱纳大学和NIH临床中心大圆桌会议上的特邀演讲。Fessler博士还在2012年美国胸科学会国际会议上担任海报会议主持人，获得了美国胸科学会颁发的职业发展奖（Carol Basbaum奖），并应邀担任ATS研究部分的评审员。 此外，Saiful Chowdhury博士是Fessler实验室的博士后研究员，最近离开了Fessler实验室，开始了一份新的教职工作，担任系里的助理教授。化学和生物化学，德克萨斯大学阿灵顿。 Fessler博士和他的同事Jim Aloor博士还完成了一项未决专利的申请，该专利描述了一种新型蛋白质，该蛋白质显示出作为炎症反应调节剂的潜力（临时专利申请#61/443，491：Modulation of Lrch 4 activity and Therapeutic Application Thereof（2011年1月17日提交;发明人：Michael B. Fessler，Jim J. Aloor））。

The Host Defense Group of the Laboratory of Respiratory Biology, Division of Intramural Research, National Institute of Environmental Health Sciences, headed by Michael B. Fessler, MD now enters its seventh year at the NIEHS since inception. We have now published several manuscripts. Publications since the last annual report include: 1) a report identifying a novel role for the cholesterol transporter ABCG1 in adaptive immune responses in the lung (Draper D et al., J Immunology 2012) 2) a collaborative publication reporting that obesity leads to abnormalities in innate immune responses in the mouse lung (Kordonowy et al., Am J Respir Cell Mol Biol 2012) 3) a collaborative publication describing a novel role for signaling lipids that derive from CGI-58 in inflammation and in insulin action (Lord CC et al, Diabetes 2012). 4) 2 review articles describing effects of cholesterol on inflammation in the lung and on innate immune responses by leukocytes (Gowdy K et al, Pulm Pharmacol Ther 2012; Azzam K et al., Trends Endocrinol Metab 2012). 5) an invited editorial commenting on a publication that describes effects of cholesterol efflux on mobilization of stem cells from the bone marrow (Suratt BT et al., Cell Stem Cell 2012) 6) a report (in press) describing a novel relationship between serum allergen-specific immunoglobulin E (a measure of atopy) and myocardial infarction in the U.S. population (Jaramillo et al., J Allergy Clin Immunol 2012) Additional accomplishments since our last report include invited talks by Dr. Fessler at Ohio State University, Johns Hopkins University, University of Missouri Kansas City, East Carolina University, and NIH Clinical Center Grand Rounds. Dr. Fessler also served as a poster session facilitator at the 2012 American Thoracic Society International Conference, received an career development award (Carol Basbaum Award) from the American Thoracic Society, and was also invited to serve as a reviewer on an ATS study section. In addition, Dr. Saiful Chowdhury, a postdoctoral fellow in Fessler laboatory, recently left Fessler laboratory to start a new faculty job as Assistant Professor in the Dept. of Chemistry and Biochemistry, University of Texas at Arlington. Dr. Fessler and his fellow, Dr. Jim Aloor, also completed filing of a pending patent that describes a novel protein that shows potential as a regulator of inflammatory responses (Provisional Patent Application #61/443,491: Modulation of Lrch4 activity and Therapeutic Application Thereof (filed January 17, 2011; inventors: Michael B. Fessler, Jim J. Aloor)).